Considering the fact that authorised in 2014, tucidinostat was regarded as a 2nd-line and subsequent therapy for PTCL sufferers in China. Clinical trials and preclinical studies in numerous hematological malignancies and strong tumors is in development. Use or redistribution of any DrugBank information or info requires a license and correct https://janez221mxi4.elbloglibre.com/profile